|
|
Volumn 56, Issue 6, 2005, Pages 645-647
|
|
The economics of the new medicare drug benefit: Implications for people with mental illnesses
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMFEBUTAMONE;
AMITRIPTYLINE;
AMOXAPINE;
CITALOPRAM;
CLOMIPRAMINE;
DESIPRAMINE;
DOXEPIN;
DULOXETINE;
ESCITALOPRAM;
FLUOXETINE;
FLUVOXAMINE;
IMIPRAMINE;
MAPROTILINE;
MIRTAZAPINE;
MONOAMINE OXIDASE INHIBITOR;
NEFAZODONE;
NORADRENALIN UPTAKE INHIBITOR;
NORTRIPTYLINE;
PAROXETINE;
PHENELZINE;
PROTRIPTYLINE;
SEROTONIN UPTAKE INHIBITOR;
SERTRALINE;
TRANYLCYPROMINE;
TRAZODONE;
TRICYCLIC ANTIDEPRESSANT AGENT;
TRIMIPRAMINE;
VENLAFAXINE;
GENERIC DRUG;
PSYCHOTROPIC AGENT;
DEPRESSION;
ECONOMICS;
HEALTH CARE PLANNING;
HEALTH INSURANCE;
HUMAN;
MEDICARE;
MENTAL DISEASE;
MENTAL HEALTH;
SHORT SURVEY;
AGED;
ARTICLE;
COST;
COST CONTROL;
DRUG COST;
INSURANCE;
LEGAL ASPECT;
MEDICAL LITERATURE;
STATISTICS;
UNITED STATES;
AGED;
COST CONTROL;
COST SHARING;
DRUG COSTS;
DRUGS, GENERIC;
HUMANS;
INSURANCE COVERAGE;
INSURANCE, PHARMACEUTICAL SERVICES;
MEDICARE;
MENTAL DISORDERS;
PHARMACOPOEIAS;
PSYCHOTROPIC DRUGS;
UNITED STATES;
|
|
EID: 20044382056
PISSN: 10752730
EISSN: None
Source Type: Journal
DOI: 10.1176/appi.ps.56.6.645 Document Type: Short Survey |
|
Times cited : (3)
|
|
References (12)
|
